J&J still plans to scale up Carvykti manufacturing this year as it awaits FDA decision on expansion to earlier lines

John­son & John­son tout­ed “sig­nif­i­cant progress” in man­u­fac­tur­ing Carvyk­ti, the CAR-T ther­a­py it de­vel­oped with Leg­end Biotech, af­ter hav­ing to find ways to im­prove pro­duc­tion last year.

“We feel good that we are pro­gress­ing with Carvyk­ti and that we will con­tin­ue to de­liv­er quar­ter-over-quar­ter growth in 2024,” CEO Joaquin Du­a­to said Tues­day morn­ing dur­ing an in­vestor call.

Dur­ing the com­pa­ny’s last earn­ings call in Oc­to­ber, J&J said that it has been work­ing to in­crease man­u­fac­tur­ing ca­pac­i­ty, both in­ter­nal­ly and through a part­ner­ship with No­var­tis to meet de­mand. The com­pa­ny has al­so not­ed that the as­set’s lentivirus com­po­nent was a pro­duc­tion bot­tle­neck.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.